Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol

Abstract Background With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is p...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Lionnel Geoffrois, Alexandre Harlé, Nassim Sahki, Aleksandra Sikanja, Florence Granel-Brocard, Alice Hervieu, Laurent Mortier, Géraldine Jeudy, Catherine Michel, Charlée Nardin, Cécile Huin-Schohn, Jean-Louis Merlin
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Subjects:	Circulating tumor DNA Melanoma Adjuvant therapy Immunotherapy Kinase inhibitors
Online Access:	https://doi.org/10.1186/s12885-023-11029-4